# SteadyMed Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/steadymed-therapeutics

- Industry: Medical Devices & Equipment
- Headquarters: San Ramon, US
- Website: www.steadymed.com
- Total disclosed funding: $2M
- Latest round: Series A (Jan 28, 2009)
- Investors on record: 2

## About

SteadyMed Therapeutics, Inc. focuses on developing and commercializing innovative therapeutic solutions, specifically targeting critical health issues like pulmonary arterial hypertension (PAH) through advanced drug delivery systems.Founded in 2005, SteadyMed Therapeutics, Inc. is based in San Ramon, US, and is dedicated to creating solutions for patients with PAH. The company was founded by Yehuda Bachar, who has a history of involvement in other ventures. In March 2015, SteadyMed completed a TRADE SALE, raising USD 216.00 mn, with Unither Pharmaceuticals as an investor. The total amount raised by the company to date is USD 216.00 mn. SteadyMed has executed 8 deals, with the most recent deal date being March 19, 2015.SteadyMed Therapeutics specializes in innovative therapies aimed at addressing critical health issues, particularly in the field of pulmonary arterial hypertension (PAH). The company’s flagship products are designed to improve patient outcomes by enhancing blood flow and reducing symptoms associated with PAH. These products are administered through various delivery systems, catering to the needs of patients and healthcare providers. SteadyMed serves healthcare institutions, pharmacies, and specialty distributors, providing these advanced therapies across North America and select international markets, including Europe and Asia.In the most recent year reported, 2017, SteadyMed Therapeutics generated revenue amounting to USD 1.07 mn, while reporting an EBITDA of USD -19.64 mn for the same year.SteadyMed Therapeutics is focusing on expanding its product line and market presence. The company is planning to launch new products specifically designed for PAH management within the next few years. Additionally, it aims to expand into new markets in Europe and Asia by 2023. The recent funding raised in March 2015 will be utilized to bolster these initiatives and support continued research and development efforts.

## Funding rounds

- Series A, Jan 28, 2009, $2M — KB Partners, Samson Venture Partners

## Investors

- KB Partners (https://capitalatlas.ai/funds/kb-partners) — Series A
- Samson Venture Partners (https://capitalatlas.ai/funds/samson-venture-partners) — Series A